Thetis Pharmaceuticals

About Thetis Pharmaceuticals

Thetis Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapies for inflammatory diseases. Utilizing a novel class of immunoregulatory autacoids known as Resolvins, discovered by researchers at Harvard Medical School, Thetis aims to resolve inflammation and promote tissue repair. The company serves patients suffering from conditions such as inflammatory bowel disease (IBD) and non-alcoholic steatohepatitis (NASH). Operating in the biopharmaceutical market, Thetis employs its proprietary HEALER technology to enhance the stability, bioavailability, and formulation properties of Resolvins and other bioactive lipids, ensuring long-term patent protection. The business model revolves around securing funding through grants and partnerships, such as the $2.3 million NIH grant and support from the Colitis Foundation, to advance their drug candidates through clinical trials. Revenue is generated through the development and potential commercialization of these first-in-class therapies.